Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
IVVD Invivyd
2.480+0.090+3.77%
Close
01/27 16:00 ET
2.470-0.010-0.40%
Post Mkt Price 01/27 17:56 ET
High
2.680
Open
2.350
Turnover
828.96K
Low
2.350
Pre Close
2.390
Volume
328.66K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Why Shares of Invivyd Jumped This Week
Invivyd (NASDAQ:IVVD) Given New $2.00 Price Target at Morgan Stanley
Invivyd (NASDAQ:IVVD – Get Rating) had its target price decreased by Morgan Stanley from $3.00 to $2.00 in a research note published on Tuesday, Benzinga reports. Morgan Stanley currently has an unde
Morgan Stanley Trims Invivyd Price Target to $2 From $3, Maintains Underweight Rating
11:34 AM EST, 01/24/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Morgan Stanley Keeps Their Sell Rating on Invivyd (IVVD)
Morgan Stanley Trims Invivyd (NASDAQ:IVVD) Target Price to $2.00
Invivyd (NASDAQ:IVVD – Get Rating) had its price objective lowered by analysts at Morgan Stanley from $3.00 to $2.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently
Invivyd Price Target Cut to $2.00/Share From $3.00 by Morgan Stanley
Invivyd Price Target Cut to $2.00/Share From $3.00 by Morgan Stanley
Invivyd Is Maintained at Underweight by Morgan Stanley
Morgan Stanley Maintains Underweight on Invivyd, Lowers Price Target to $2
Morgan Stanley analyst Matthew Harrison maintains Invivyd (NASDAQ:IVVD) with a Underweight and lowers the price target from $3 to $2.
Invivyd Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/24/2023 -1.96% Morgan Stanley $3 → $2 Maintains Underweight 09/14/2022 47.06% Morgan Stanley → $3 Maint
12 Health Care Stocks Moving In Monday's After-Market Session
GainersAxcella Health (NASDAQ:AXLA) shares moved upwards by 49.9% to $0.65 during Monday's after-market session. Today's trading volume for this security ended up closing at 1.2 million shares, which
Company Overview
More
Invivyd, Inc.(formerly Adagio Therapeutics, Inc.) engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.
CEO： Mr. David Hering
Market： NASDAQ
Listing Date： 08/06/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet